Evidence map›Paper›PMID 22022524›Full record

ArticlePloS one2011

Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials.

Lycias Zembe, Wendy A Burgers, Heather B Jaspan, Linda-Gail Bekker, Helba Bredell, Gwynneth Stevens, Jill Gilmour, Josephine H Cox, Patricia Fast, Peter Hayes and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Lycias ZembeDivision of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Wendy A Burgers
Heather B Jaspan
Linda-Gail Bekker
Helba Bredell
Gwynneth Stevens
Jill Gilmour
Josephine H Cox
Patricia Fast
Peter Hayes
Eftyhia Vardas
Carolyn Williamson
Clive M Gray
International AIDS Vaccine Initiative · USUniversity of Cape Town · ZADesmond Tutu HIV Foundation · ZANational Institute for Communicable DiseasesStellenbosch University · ZA

Funding

University of Cape Town Clinical Trials Unit (UCTCTU)UM1AI069519 · NIAID · UNIVERSITY OF CAPE TOWN · PI Linda-Gail Bekker · 2012 to 2026
$36.3M
Cape Town Clinical Trials Unit (CT-CTU) for HIV/AIDS Prevention & TreatmentU01AI069519 · NIAID · UNIVERSITY OF CAPE TOWN · PI WOOD, ROBIN · 2007 to 2011
$4.6M
NIAID NIH HHS UM1 AI069519
6 · The paper itself

Abstract

The genetic diversity of HIV-1 across the globe is a major challenge for developing an HIV vaccine. To facilitate immunogen design, it is important to characterize clusters of commonly targeted T-cell epitopes across different HIV clades. To address this, we examined 39 HIV-1 clade C infected individuals for IFN-γ Gag-specific T-cell responses using five sets of overlapping peptides, two sets matching clade C vaccine candidates derived from strains from South Africa and China, and three peptide sets corresponding to consensus clades A, B, and D sequences. The magnitude and breadth of T-cell responses against the two clade C peptide sets did not differ, however clade C peptides were preferentially recognized compared to the other peptide sets. A total of 84 peptides were recognized, of which 19 were exclusively from clade C, 8 exclusively from clade B, one peptide each from A and D and 17 were commonly recognized by clade A, B, C and D. The entropy of the exclusively recognized peptides was significantly higher than that of commonly recognized peptides (p = 0.0128) and the median peptide processing scores were significantly higher for the peptide variants recognized versus those not recognized (p = 0.0001). Consistent with these results, the predicted Major Histocompatibility Complex Class I IC(50) values were significantly lower for the recognized peptide variants compared to those not recognized in the ELISPOT assay (p<0.0001), suggesting that peptide variation between clades, resulting in lack of cross-clade recognition, has been shaped by host immune selection pressure. Overall, our study shows that clade C infected individuals recognize clade C peptides with greater frequency and higher magnitude than other clades, and that a selection of highly conserved epitope regions within Gag are commonly recognized and give rise to cross-clade reactivities.

Indexed as

Clinical Trials as TopicAdultAIDS VaccinesAmino Acid SequenceAntigen PresentationCross ReactionsEpitopesgag Gene Products, Human Immunodeficiency VirusHistocompatibility Antigens Class IHIV-1HumansMiddle AgedMolecular Sequence DataPeptidesProtein Processing, Post-TranslationalT-LymphocytesAIDS VaccinesEpitopesgag Gene Products, Human Immunodeficiency VirusHistocompatibility Antigens Class IPeptides

Identifiers

PMID22022524
PMCPMC3192159
OpenAlexW1997847410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.